Iterum Therapeutics Plc (NASDAQ: ITRM) kicked off on Monday, up 8.20% from the previous trading day, before settling in for the closing price of $1.22. Over the past 52 weeks, ITRM has traded in a range of $0.67-$2.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -39.15% over the last five years. While this was happening, its average annual earnings per share was recorded 68.93%. With a float of $21.95 million, this company’s outstanding shares have now reached $22.71 million.
The firm has a total of 14 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.99%, operating margin of -1460.11%, and the pretax margin is -1066.98%.
Iterum Therapeutics Plc (ITRM) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Iterum Therapeutics Plc is 3.33%, while institutional ownership is 1.47%. The most recent insider transaction that took place on Dec 22 ’23, was worth 35,000. In this transaction Director of this company bought 25,000 shares at a rate of $1.40, taking the stock ownership to the 113,754 shares. Before that another transaction happened on Dec 18 ’23, when Company’s Director bought 10,000 for $1.84, making the entire transaction worth $18,442. This insider now owns 88,754 shares in total.
Iterum Therapeutics Plc (ITRM) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.3 earnings per share (EPS), higher than consensus estimate (set at -0.91) by 0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.93% per share during the next fiscal year.
Iterum Therapeutics Plc (NASDAQ: ITRM) Trading Performance Indicators
Take a look at Iterum Therapeutics Plc’s (ITRM) current performance indicators. Last quarter, stock had a quick ratio of 0.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Iterum Therapeutics Plc (ITRM)
Analysing the last 5-days average volume posted by the [Iterum Therapeutics Plc, ITRM], we can find that recorded value of 2.38 million was better than the volume posted last year of 0.95 million. As of the previous 9 days, the stock’s Stochastic %D was 17.85%. Additionally, its Average True Range was 0.19.
During the past 100 days, Iterum Therapeutics Plc’s (ITRM) raw stochastic average was set at 33.86%, which indicates a significant increase from 23.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 252.93% in the past 14 days, which was higher than the 118.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1150, while its 200-day Moving Average is $1.3503. Now, the first resistance to watch is $1.3833. This is followed by the second major resistance level at $1.4467. The third major resistance level sits at $1.5433. If the price goes on to break the first support level at $1.2233, it is likely to go to the next support level at $1.1267. Should the price break the second support level, the third support level stands at $1.0633.
Iterum Therapeutics Plc (NASDAQ: ITRM) Key Stats
The company with the Market Capitalisation of 28.34 million has total of 22,706K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -38,370 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -5,000 K.
